| Pharmaceutical Information |
| Drug Name |
Etoricoxib |
| Drug ID |
BADD_D00856 |
| Description |
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US. |
| Indications and Usage |
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. |
| Marketing Status |
approved; investigational |
| ATC Code |
M01AH05 |
| DrugBank ID |
DB01628
|
| KEGG ID |
D03710
|
| MeSH ID |
D000077613
|
| PubChem ID |
123619
|
| TTD Drug ID |
D09MGR
|
| NDC Product Code |
42765-006; 68554-0053 |
| UNII |
WRX4NFY03R
|
| Synonyms |
Etoricoxib | MK 0663 | MK-0663 | MK0663 | Arcoxia | L-791456 | L 791456 | L791456 |
|
| Chemical Information |
| Molecular Formula |
C18H15ClN2O2S |
| CAS Registry Number |
202409-33-4 |
| SMILES |
CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
